Evidence map›Paper›PMID 41320759›Full record

ArticleMilitary Medical Research2025

Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels-Alder reaction-based self-immolative molecular cage strategy.

Meng-Die Yang, Kang Fang, Xiao-Yi Zhang, Gang Yang, He-Qing Yi, Le Cai, Shan-Shan Qin, Xin-Da Yang, Rong Rong, Shuo Shi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Military Medical Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meng-Die Yang *Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
Kang Fang *Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
Xiao-Yi Zhang *Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
Gang YangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
He-Qing YiDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Le CaiDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Shan-Shan QinDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
Xin-Da YangDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China.
Rong RongCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Shuo ShiDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China. shishuo@tongji.edu.cn.
Fei YuDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, School of Chemical Science and Engineering, Shanghai, 200072, China. 0910110013yufei@tongji.edu.cn.ORCID 0000-0003-2951-725X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted alpha therapy (TAT) has emerged as a promising strategy for cancer treatment by selectively delivering high linear energy transfer (LET) alpha-emitters to tumor cells while minimizing off-target toxicity. However, the clinical translation of alpha-emitters, particularly radium-223 (

methodsHerein, a dual-locked pretargeted strategy was developed integrating platinum

resultsThis caged dual-locked approach enables precise pretargeted accumulation at the tumor site, followed by rapid dissociation and controlled release of

conclusionsThese findings underscore the potential of dual-locked pretargeted strategies to advance TAT by improving therapeutic efficacy and addressing the critical challenge of radionuclide leakage, paving the way for next-generation precision-targeted radiopharmaceuticals.

Indexed as

Alpha ParticlesCycloaddition ReactionImmunotherapyNeoplasmsAnimalsCell Line, TumorHumansMiceRadiumRadiumRadium-223Alpha-emittersBioorthogonal click chemistryRadium-223 (223Ra)Targeted alpha therapy (TAT)

Identifiers

PMID41320759
PMCPMC12667170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.